GENEART: Applied Biosystems Deutschland GmbH holds 95% of GENEART Shares
Geneart AG / GENEART: Applied Biosystems Deutschland GmbH holds 95% of GENEART Shares processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Regensburg, August 3, 2010 - The majority shareholder of GENEART AG, Regensburg,
Applied Biosystems Deutschland GmbH, Darmstadt ("ABD"), directly holds more than
95% of all shares in GENEART AG as noticed by ABD. ABD informed the management
board of GENEART AG about this fact by letter dated August/3/2010.
By virtue of this letter ABD also requested that the general meeting of GENEART
AG may resolve upon the transfer of shares of the minority shareholders to ABD
against payment of an adequate cash consideration (Section 327a para. 1 sentence
1 German Stock Corporation Act, Aktiengesetz, "AktG", so-called Squeeze-Out).
The management board of GENEART AG intends to comply with this request and to
convene an extraordinary general meeting. This meeting will presumably take
place at a time in the last quarter of 2010.
GENEART and ABD still intend to conclude a domination agreement (Section 291 et
seq. AktG) with GENEART AG as dominated and ABD as dominating entity. The
domination agreement shall be submitted for approval to this extraordinary
For further inquiries, please contact:
Dr. Karoline StÃ¼rmer
Phone: +49-(0)941-942 76-417
Fax: +49-(0)941-942 76-711
Better Orange IR & HV AG
This document may contain estimates, prognoses and opinions about company plans
and objectives, products or services, future results, opinions about these
results or opinions leading up to these results. All these projections into the
future are subject to risk, uncertainty and unforeseeable change outside the
control of the GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.
About GENEART AG:
In 2000 GENEART entered the Gene Synthesis market and has since become the
global market leader. Today, the company is one of the leading specialists in
the Synthetic Biology field. Experts at GENEART provide key technologies for the
development and production of new therapeutics and vaccines. Customers also take
advantage of GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct bacteria,
which produce complex biopolymers or break down polymers, such as synthetics,
petroleum components, etc. GENEART's service portfolio ranges from the
optimization and production of synthetic genes according to DIN EN ISO
9001:2008, to the generation of gene variants or complex gene libraries and the
production of cell lines, to the development and production of DNA and protein
based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART
Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about
180 people. The company is listed on the German Stock Exchange since May 2006.
Since April 2010, U.S.- based Life Technologies Corporation, one of the leading
biotechnology companies worldwide with 2009 revenues of USD 3.3B and about
9,000 employees, is the majority shareholder of GENEART AG.
--- End of Message ---
Josef-Engert-Str.11 Regensburg Germany
Listed: Freiverkehr in BÃ¶rse Stuttgart,
Freiverkehr in BÃ¶rse Berlin,
Freiverkehr in BÃ¶rse DÃ¼sseldorf,
Open Market (Freiverkehr) in Frankfurter WertpapierbÃ¶rse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Geneart AG via Thomson Reuters ONE